{"id":"alanine","rwe":[],"_fda":{"id":"488d78ac-3cd2-4593-8968-2992fe59bb49","set_id":"2d212e10-7e08-4aeb-b63f-dcc927897769","openfda":{"nui":["N0000175780","M0000922"],"unii":["OF5P57N2ZX","94ZLA3W45F","30KYC7MIAI","3KX376GY7L","TE7660XO1C","4QD397987E","04Y7590D77","GMW67QNF9C","TTL6G7LIWZ","AE28F7PNPL","47E5O17Y3R","9DLQ4CIU6V","452VLY9402","1EQV5MLY3D","2ZD004190S","8DUH1N11BX","42HK56048U","HG18B9YRS7"],"route":["INTRAVENOUS"],"rxcui":["831426","831430"],"spl_id":["488d78ac-3cd2-4593-8968-2992fe59bb49"],"brand_name":["Aminosyn-PF"],"spl_set_id":["2d212e10-7e08-4aeb-b63f-dcc927897769"],"package_ndc":["0990-4178-03"],"product_ndc":["0990-4178"],"generic_name":["ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, AND TYROSINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Amino Acids [CS]"],"substance_name":["ALANINE","ARGININE","ASPARTIC ACID","GLUTAMIC ACID","GLYCINE","HISTIDINE","ISOLEUCINE","LEUCINE","LYSINE ACETATE","METHIONINE","PHENYLALANINE","PROLINE","SERINE","TAURINE","THREONINE","TRYPTOPHAN","TYROSINE","VALINE"],"pharm_class_epc":["Amino Acid [EPC]"],"manufacturer_name":["ICU Medical Inc."],"application_number":["NDA019398"],"is_original_packager":[true]},"version":"4","warnings":["WARNINGS Safe, effective use of parenteral nutrition requires a knowledge of nutrition as well as clinical expertise in recognition and treatment of the complications which can occur. FREQUENT EVALUATION AND LABORATORY DETERMINATIONS ARE NECESSARY FOR PROPER MONITORING OF PARENTERAL NUTRITION. Studies should include blood sugar, serum proteins, kidney and liver function tests, electrolytes, hemogram, carbon dioxide content, serum osmolalities, blood cultures, and blood ammonia levels. Administration of amino acids in the presence of impaired renal function or gastrointestinal bleeding may augment an already elevated blood urea nitrogen. Patients with azotemia from any cause should not be infused with amino acids without regard to total nitrogen intake. Administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the solutions. Administration of amino acid solutions to a patient with hepatic insufficiency may result in plasma amino acid imbalances, hyperammonemia, prerenal azotemia, stupor and coma. Hyperammonemia is of special significance in infants , as its occurrence in the syndrome caused by genetic metabolic defects is sometimes associated, although not necessarily in a causal relationship, with mental retardation. This reaction appears to be dose-related and is more likely to develop during prolonged therapy. It is essential that blood ammonia be measured frequently in infants. Conservative doses of amino acids should be given, dictated by the nutritional status of the patient. Should symptoms of hyperammonemia develop, amino acid dosage levels should be reduced and titrated against serum ammonia levels. WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration."],"pregnancy":["Pregnancy Category C Animal reproduction studies have not been conducted with Aminosyn-PF 7%. It is also not known whether Aminosyn-PF 7% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Aminosyn-PF 7% should be given to a pregnant woman only if clearly needed."],"overdosage":["OVERDOSAGE In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS and PRECAUTIONS ."],"description":["DESCRIPTION Aminosyn ® -PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is a sterile, nonpyrogenic solution for intravenous infusion. Aminosyn ® -PF 7% is oxygen sensitive. The formulation is described below: Aminosyn-PF 7% An Amino Acid Injection — Pediatric Formula Essential Amino Acids (mg/100 mL) Isoleucine 534 Leucine 831 Lysine (acetate)* 475 Methionine 125 Phenylalanine 300 Threonine 360 Tryptophan 125 Valine 452 * Amount cited is for lysine alone and does not include the acetate salt. Nonessential Amino Acids (mg/100 mL) Alanine 490 Arginine 861 L-Aspartic Acid 370 L-Glutamic Acid 576 Glycine 270 Histidine 220 Proline 570 Serine 347 Taurine 50 Tyrosine 44 Electrolytes (mEq/L) Sodium (Na + ) (mEq/L) None Potassium (K + ) (mEq/L) None Chloride (Clˉ) (mEq/L) None Acetate (C 2 H 3 O 2 ˉ) a (mEq/L) 32.5 a From lysine acetate. Product Characteristics Protein Equivalent (Approx. grams/L) 70 Total Nitrogen (grams/L) 10.69 Osmolarity (mOsmol/L) 561 pH (range) 5.5 (5.0 to 6.5) The formulas for the individual amino acids present in Aminosyn-PF 7% are as follows: Essential Amino Acids Isoleucine, USP C 6 H 13 NO 2 Leucine, USP C 6 H 13 NO 2 Lysine Acetate, USP C 6 H 14 N 2 O 2 • CH 3 COOH Methionine, USP C 5 H 11 NO 2 S Phenylalanine, USP C 9 H 11 NO 2 Threonine, USP C 4 H 9 NO 3 Tryptophan, USP C 11 H 12 N 2 O 2 Valine, USP C 5 H 11 NO 2 Nonessential Amino Acids Alanine, USP C 3 H 7 NO 2 Glycine, USP C 2 H 5 NO 2 Arginine, USP C 6 H 14 N 4 O 2 L-Aspartic Acid C 4 H 7 NO 4 HO 2 CCH 2 CH(NH 2 )CO 2 H L-Glutamic Acid C 5 H 9 NO 4 HO 2 CCH 2 CHCH(NH 2 )CO 2 H Histidine, USP C 6 H 9 N 3 O 2 Proline, USP C 5 H 9 NO 2 Serine, USP C 3 H 7 NO 3 Taurine C 2 H 7 NO 3 S Tyrosine, USP C 9 H 11 NO 3 The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period."],"precautions":["PRECAUTIONS Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. Significant deviations from normal concentrations may require the use of additional electrolyte supplements. Strongly hypertonic nutrient solutions should be administered via an intravenous catheter placed in a central vein, preferably the superior vena cava. Care should be taken to avoid circulatory overload, particularly in patients with cardiac insufficiency. Special care must be taken when giving hypertonic dextrose to a diabetic or pre-diabetic patient. To prevent severe hyperglycemia in such patients, insulin may be required. Administration of glucose at a rate exceeding the patient's utilization rate may lead to hyperglycemia, coma, and death. The effect of infusion of amino acids, without dextrose, upon carbohydrate metabolism of children is not known at this time. It is essential to provide adequate exogenous dextrose calories concurrently with amino acids. Administration of amino acids without carbohydrates may result in the accumulation of ketone bodies in the blood. Correction of this ketonemia may be achieved by the administration of carbohydrate. Essential fatty acid deficiency (EFAD) is becoming increasingly recognized in patients on long term TPN (more than 5 days). The use of fat emulsion to provide 4 — 10% of total caloric intake as linoleic acid may prevent EFAD. Peripheral administration of Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) requires appropriate dilution and provision of adequate calories. Care should be taken to assure proper placement of the needle within the lumen of the vein. The venipuncture site should be inspected frequently for signs of infiltration. If venous thrombosis or phlebitis occurs, discontinue infusions or change infusion site and initiate appropriate treatment. Extraordinary electrolyte losses such as may occur during protracted nasogastric suction, vomiting, diarrhea, or gastrointestinal fistula drainage may necessitate additional electrolyte supplementation. Metabolic acidosis can be prevented or readily controlled by adding a portion of the cations in the electrolyte mixture as acetate salts and in the case of hyperchloremic acidosis, by keeping the total chloride content of the infusate to a minimum. Aminosyn-PF 7% contains no chloride. Aminosyn-PF 7% contains no added phosphorus. Patients, especially those with hypophosphatemia, may require the addition of phosphate. To prevent hypocalcemia, calcium supplementation should always accompany phosphate administration. To assure adequate intake, serum levels should be monitored frequently. Aminosyn-PF 7% contains no more than 25 mcg/L of aluminum. To minimize the risk of possible incompatabilities arising from mixing this solution with other additives that may be prescribed, the final infusate should be inspected for cloudiness or precipitation immediately after mixing, prior to administration, and periodically during administration. SPECIAL PRECAUTIONS FOR CENTRAL INFUSIONS ADMINISTRATION BY CENTRAL VENOUS CATHETER SHOULD BE USED ONLY BY THOSE FAMILIAR WITH THIS TECHNIQUE AND ITS COMPLICATIONS. Central vein infusion (with added concentrated carbohydrate solutions) of amino acid solutions requires a knowledge of nutrition as well as clinical expertise in recognition and treatment of complications. Attention must be given to solution preparation, administration and patient monitoring. IT IS ESSENTIAL THAT A CAREFULLY PREPARED PROTOCOL, BASED ON CURRENT MEDICAL PRACTICES, BE FOLLOWED, PREFERABLY BY AN EXPERIENCED TEAM. SUMMARY HIGHLIGHTS OF COMPLICATIONS (See also Current Medical Literature). 1. Technical The placement of a central venous catheter should be regarded as a surgical procedure. One should be fully acquainted with various techniques of catheter insertion. For details of technique and placement sites, consult the medical literature. X-ray is the best means of verifying catheter placement. Complications known to occur from the placement of central venous catheters are pneumothorax, hemothorax, hydrothorax, artery puncture and transection, injury to the brachial plexus, malposition of the catheter, formation of arteriovenous fistula, phlebitis, thrombosis and air and catheter emboli. 2. Septic The constant risk of sepsis is present during administration of total parenteral nutrition. It is imperative that the preparation of the solution and the placement and care of catheters be accomplished under strict aseptic conditions. Solutions should ideally be prepared in the hospital pharmacy under a laminar flow hood using careful aseptic technique to avoid inadvertent touch contamination. Solutions should be used promptly after mixing. Storage should be under refrigeration and limited to a brief period of time, preferably less than 24 hours. Administration time for a single container and set should never exceed 24 hours. 3. Metabolic The following metabolic complications have been reported with TPN administration: Metabolic acidosis and alkalosis, hypophosphatemia, hypocalcemia, osteoporosis, hyperglycemia and glycosuria, rebound hypoglycemia, osmotic diuresis and dehydration, elevated liver enzymes, hypo- and hypervitaminosis, electrolyte imbalances and hyperammonemia in children. Frequent evaluations are necessary especially during the first few days of therapy to prevent or minimize these complications. Administration of glucose at a rate exceeding the patient's utilization rate may lead to hyperglycemia, coma and death. CLINICAL EVALUATION AND LABORATORY DETERMINATIONS, AT THE DISCRETION OF THE ATTENDING PHYSICIAN ARE NECESSARY FOR PROPER MONITORING DURING ADMINISTRATION. Do not withdraw venous blood for blood chemistries through the peripheral infusion site, as interference with estimations of nitrogen-containing substances may occur. Blood studies should include glucose, urea nitrogen, serum electrolytes, ammonia, cholesterol, acid-base balance, serum proteins, kidney and liver function tests, osmolarity and hemogram. White blood count and blood cultures are to be determined if indicated. Urinary osmolality and glucose should be determined as necessary. Pregnancy Category C Animal reproduction studies have not been conducted with Aminosyn-PF 7%. It is also not known whether Aminosyn-PF 7% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Aminosyn-PF 7% should be given to a pregnant woman only if clearly needed."],"how_supplied":["HOW SUPPLIED NDC No. Concentration Container (mL) 0409-4178-03 Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection - 500 0990-4178-03 pediatric formula) ICU Medical is transitioning NDC codes from the \"0409\" to a \"0990\" labeler code. Both NDC codes are expected to be in the market for a period of time. Store at 20 to 25ºC (68 to 77ºF). [See USP Controlled Room Temperature.] Protect from freezing. Avoid exposure to light. Revised: August, 2018 EN-4682 ICU Medical, Inc., Lake Forest, Illinois, 60045 USA"],"effective_time":"20251017","adverse_reactions":["ADVERSE REACTIONS Local reactions consisting of erythema, phlebitis and thrombosis at the infusion site have occurred with peripheral intravenous infusion of amino acids particularly if other substances, such as antibiotics, are also administered through the same site. In such cases the infusion site should be changed promptly to another vein. Use of large peripheral veins, inline filters, and slowing the rate of infusion may reduce the incidence of local venous irritation. Electrolyte additives should be spread throughout the day. Irritating additive medications may need to be injected at another venous site. Generalized flushing, fever and nausea also have been reported during peripheral infusions of amino acid solutions. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary."],"contraindications":["CONTRAINDICATIONS Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is contraindicated in patients with untreated anuria, hepatic coma, inborn errors of amino acid metabolism (including those involving branched chain amino acid metabolism such as maple syrup urine disease and isovaleric acidemia), or hypersensitivity to one or more amino acids present in the solution."],"description_table":["
Aminosyn-PF 7%An Amino Acid Injection — Pediatric Formula
Essential Amino Acids (mg/100 mL)
Isoleucine534
Leucine831
Lysine (acetate)*475
Methionine125
Phenylalanine300
Threonine360
Tryptophan125
Valine452
","
Nonessential Amino Acids (mg/100 mL)
Alanine490
Arginine861
L-Aspartic Acid370
L-Glutamic Acid576
Glycine270
Histidine220
Proline570
Serine347
Taurine50
Tyrosine44
","
Electrolytes (mEq/L)
Sodium (Na+) (mEq/L)None
Potassium (K+) (mEq/L)None
Chloride (Clˉ) (mEq/L)None
Acetate (C2H3O2ˉ)a (mEq/L)32.5
","
Product Characteristics
Protein Equivalent (Approx. grams/L)70
Total Nitrogen (grams/L)10.69
Osmolarity (mOsmol/L)561
pH (range)5.5 (5.0 to 6.5)
","
Essential Amino Acids
Isoleucine, USPC6H13NO2
Leucine, USPC6H13NO2
Lysine Acetate, USPC6H14N2O2 • CH3COOH
Methionine, USPC5H11NO2S
Phenylalanine, USPC9H11NO2
Threonine, USPC4H9NO3
Tryptophan, USPC11H12N2O2
Valine, USPC5H11NO2
","
Nonessential Amino Acids
Alanine, USPC3H7NO2
Glycine, USPC2H5NO2
Arginine, USPC6H14N4O2
L-Aspartic AcidC4H7NO4
HO2CCH2CH(NH2)CO2H
L-Glutamic AcidC5H9NO4
HO2CCH2CHCH(NH2)CO2H
Histidine, USPC6H9N3O2
Proline, USPC5H9NO2
Serine, USPC3H7NO3
TaurineC2H7NO3S
Tyrosine, USPC9H11NO3
"],"precautions_table":["
SPECIAL PRECAUTIONS FOR CENTRAL INFUSIONS
ADMINISTRATION BY CENTRAL VENOUS CATHETER SHOULD BE USED ONLY BY THOSE FAMILIAR WITH THIS TECHNIQUE AND ITS COMPLICATIONS.
"],"how_supplied_table":["
NDC No.ConcentrationContainer (mL)
0409-4178-03Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection -500
0990-4178-03pediatric formula)
"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Aminosyn-PF 7% Sulfite-Free, (an amino acid injection — pediatric formula) contains a mixture of essential and nonessential amino acids as well as taurine. The amino acid composition has been specifically formulated to provide a well-tolerated nitrogen source for nutritional support and therapy for infants and young children. When administered in conjunction with a cysteine hydrochloride additive, Aminosyn-PF 7% results in plasma amino acid concentrations approximating a profile consistent with that of a breast-fed infant. The rationale for Aminosyn-PF 7% is based on the observation of inadequate levels of essential amino acids in the plasma of infants receiving total parenteral nutrition (TPN) using conventional amino acid solutions. Clinical studies in infants who required TPN therapy showed that infusion of Aminosyn-PF 7% resulted in plasma amino acid concentrations approximating those of normal breast or formula fed infants. In addition, weight gains, nitrogen balance, and serum protein concentrations were consistent with an improving nutritional status. When infused with hypertonic dextrose as a calorie source, supplemented with cysteine hydrochloride, electrolytes, vitamins, and minerals, Aminosyn-PF 7% provides TPN for infants and young children, with the exception of essential fatty acids. It is thought that the acetate from lysine acetate under the conditions of parenteral nutrition, does not impact net acid-base balance when renal and respiratory functions are normal. Clinical evidence seems to support this thinking; however, confirmatory experimental evidence is not available. The amounts of sodium and acetate in Aminosyn-PF 7% are not of clinical significance. The addition of a cysteine hydrochloride additive will contribute to the chloride load. The electrolyte content of any additives that are introduced should be carefully considered and included in input computations. The human newborn conjugates bile with taurine which becomes the primary method of biliary excretion. Taurine deficiency because of its effect on bile salt conjugation and, therefore, on bile salt flow may be of major importance in the genesis of cholestasis. Taurine has also been shown to play a role in central nervous system development."],"indications_and_usage":["INDICATIONS AND USAGE Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is indicated for the nutritional support of infants (including those of low birth weight) and young children requiring TPN via either central or peripheral infusion routes. Parenteral nutrition with Aminosyn-PF 7% is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young children where (1) the alimentary tract by the oral gastrostomy, or jejunostomy route, cannot or should not be used or adequate protein intake is not feasible by these routes, (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. Dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutrition support, and vein tolerance. See DOSAGE AND ADMINISTRATION for additional information. Central Venous Infusion Central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis in hypercatabolic or severely depleted infants or those requiring long-term parenteral nutrition. Peripheral Parenteral Nutrition For moderately catabolic or depleted patients in whom the central venous route is not indicated, diluted amino acid solutions mixed with 5 to 10% dextrose solutions may be infused by peripheral vein, supplemented, if desired, with fat emulsion."],"spl_unclassified_section":["AN AMINO ACID INJECTION - PEDIATRIC FORMULA Flexible Plastic Container Rx only"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION The total daily dose of the solution depends on the daily protein requirements and on the patient's metabolic and clinical response. Pediatric requirements for parenteral nutrition are constrained by the greater relative fluid requirements of the infant and greater caloric requirements per kilogram than in the adult. The recommended intravenous dose of Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is up to 2.5 g amino acid/kg/day for infants up to 10 kg. For infants and children larger than 10 kg, the total daily dose of amino acids should be up to 25 g amino acids/day for the first 10 kg of body weight plus 1 to 1.25 g amino acid for each kg of body weight over 10 kg. Initial amino acid dosage levels of 1 g/kg/day may be increased gradually in increments of 0.5 g/kg/day to approximate desired intake levels. Aminosyn-PF 7% should be diluted with dextrose prior to use. Nonprotein calories should constitute approximately 100 to 130 kcal/kg/day. Part of the nonprotein caloric requirement may be provided as lipid emulsion administered concurrently to provide up to 60% of daily calories at a dose not to exceed 4 g fat/kg/day. Fluid intake for the infant receiving central venous TPN should be approximately 125 mL/kg/day (range: 100 to 175 mL/kg/day), depending on the clinical condition of the patient. Premature infants with respiratory distress syndrome suspected of having a patent ductus arteriosus should be given fluids more cautiously. Cysteine is considered to be an essential amino acid for infants, especially preterm infants with potentially immature enzyme pathways. Therefore, addition of a cysteine supplement to the TPN admixture is recommended. The intake of cysteine by the preterm infant ingesting maternal milk is approximately 78 mg/kg/day. The suggested intravenous dosage level for Cysteine Hydrochloride Injection, USP is 500 mg (10 mL) for every 12.5 g (179 mL) of Aminosyn-PF 7% administered (see package insert for Cysteine Hydrochloride Injection, USP). In order to avoid potential insolubility of cysteine hydrochloride in admixtures, the foregoing concentration should not be exceeded. In many patients, provision of adequate calories in the form of hypertonic dextrose may require the administration of exogenous insulin to prevent hyperglycemia and glycosuria. To prevent rebound hypoglycemia, a solution containing 5% dextrose should be administered when hypertonic dextrose solutions are abruptly discontinued. SERUM ELECTROLYTES SHOULD BE MONITORED FREQUENTLY. Electrolytes may be added to the nutrient solution as indicated by the patient's clinical condition and laboratory determinations of plasma values. Major electrolytes are sodium, chloride, potassium, phosphate, magnesium and calcium. Daily administration of intravenous vitamin supplements including a complete complement of fat and water-soluble vitamins is required. Trace metal additives including zinc, copper, manganese, and chromium should also be provided, especially when long-term parenteral therapy is anticipated. Calcium and phosphorus are added to the solution as indicated. Potentially incompatible ions such as calcium and phosphate may be added to alternate infusate bottles to avoid precipitation. In patients with hyperchloremic or other metabolic acidosis, sodium and potassium may be added as the acetate or lactate salts to provide bicarbonate alternates. Bicarbonate should not be administered during infusion of the nutritional solution unless deemed absolutely necessary. Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store. To ensure the precise delivery of the small volumes of fluid necessary for total parenteral nutrition in infants, accurately calibrated and reliable infusion systems should be used. Central Venous Nutrition Hypertonic mixtures of amino acids and dextrose may be safely administered by continuous infusion through a central venous catheter with the tip located in the superior vena cava. Initial infusion rates should be slow, and gradually increased to the recommended 60-125 mL per kilogram body weight per day. If administration rate should fall behind schedule, no attempt to \"catch up\" to planned intake should be made. In addition to meeting protein needs, the rate of administration, particularly during the first few days of therapy, is governed by the patient's glucose tolerance. Daily intake of amino acids and dextrose should be increased gradually to the maximum required dose as indicated by frequent determinations of glucose levels in blood and urine. Peripheral Parenteral Nutrition For patients in whom the central venous route is not indicated and who can consume adequate calories enterally, Aminosyn-PF 7% may be administered by peripheral vein with parenteral nonprotein calories. The concentration of dextrose in the final admixture is 5 to 10%, and simultaneous administration of lipid emulsion is recommended both as a calorie source and to attenuate the potentially irritating effects of the hypertonic nutritional admixture. Fat emulsion may comprise up to 60% of the daily caloric intake at a dosage level not to exceed 4 g fat/kg/day. It is essential that peripheral infusion be accompanied by adequate caloric intake. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. COLOR VARIATION FROM PALE YELLOW TO YELLOW IS NORMAL AND DOES NOT ALTER EFFICACY. WARNING: Do not use flexible container in series connections."],"spl_product_data_elements":["Aminosyn-PF ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, and TYROSINE ISOLEUCINE ISOLEUCINE LEUCINE LEUCINE LYSINE ACETATE LYSINE METHIONINE METHIONINE PHENYLALANINE PHENYLALANINE THREONINE THREONINE TRYPTOPHAN TRYPTOPHAN VALINE VALINE ALANINE ALANINE ARGININE ARGININE ASPARTIC ACID ASPARTIC ACID GLUTAMIC ACID GLUTAMIC ACID GLYCINE GLYCINE HISTIDINE HISTIDINE PROLINE PROLINE SERINE SERINE TAURINE TAURINE TYROSINE TYROSINE WATER"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 500 mL Bag Label 500 mL NDC 0990-4178-03 Aminosyn ® -PF 7% Sulfite-Free AN AMINO ACID INJECTION – PEDIATRIC FORMULA EACH 100 mL CONTAINS: TOTAL AMINO ACIDS APPROX. 7 g. ESSENTIAL AMINO ACIDS/100 mL : ISOLEUCINE 534 mg; LEUCINE 831 mg; LYSINE (AS ACETATE SALT) 475 mg; METHIONINE 125 mg; PHENYLALANINE 300 mg; THREONINE 360 mg; TRYPTOPHAN 125 mg; VALINE 452 mg. NONESSENTIAL AMINO ACIDS/100 mL: TYROSINE 44 mg; ALANINE 490 mg; ARGININE 861 mg; GLYCINE 270 mg; PROLINE 570 mg; HISTIDINE 220 mg; SERINE 347 mg; L-GLUTAMIC ACID 576 mg; L-ASPARTIC ACID 370 mg; TAURINE 50 mg. ELECTROLYTES (mEq/LITER): ACETATE 32.5. pH 5.5 (5.0 to 6.5) 561 mOsmol/LITER SPECIFIC GRAVITY = 1.02 ADDITIVES MAY BE INCOMPATIBLE. CONSULT WITH PHARMACIST, IF AVAILABLE. WHEN INTRODUCING ADDITIVES, USE ASEPTIC TECHNIQUE, MIX THOROUGHLY AND DO NOT STORE. SINGLE DOSE CONTAINER. CONTAINS NO BACTERIOSTAT. DISCARD UNUSED PORTION. FOR I.V. USE. USUAL DOSAGE: SEE INSERT. STERILE, NONPYROGENIC. STORE AT 20 TO 25°C (68 TO 77°F). [SEE USP CONTROLLED ROOM TEMPERATURE.] AVOID EXCESSIVE HEAT. PROTECT FROM FREEZING. AVOID EXPOSURE TO LIGHT. USE ONLY IF SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED. MUST NOT BE USED IN SERIES CONNECTIONS. RX ONLY IM-4405 3 v CONTAINS DEHP icumedical ICU Medical, Inc., Lake Forest, Illinois, 60045, USA PRINCIPAL DISPLAY PANEL - 500 mL Bag Label","PRINCIPAL DISPLAY PANEL - 500 mL Overwrap Label TO OPEN – TEAR AT NOTCH 500 mL NDC 0990-4178-03 Aminosyn ® -PF 7% Sulfite-Free AN AMINO ACID INJECTION — PEDIATRIC FORMULA Each 100 mL contains: Total amino acids approx. 7 g. Essential Amino Acids/100 mL: Isoleucine 534 mg; leucine 831 mg; lysine (as acetate salt) 475 mg; methionine 125 mg; phenylalanine 300 mg; threonine 360 mg; tryptophan 125 mg; valine 452 mg. Nonessential Amino Acids/100 mL: Tyrosine 44 mg; alanine 490 mg; arginine 861 mg; glycine 270 mg; proline 570 mg; histidine 220 mg; serine 347 mg; L-glutamic acid 576 mg; L-aspartic acid 370 mg; taurine 50 mg. Electrolytes (mEq/Liter): Acetate 32.5. 561 mOsmol/Liter pH 5.5 (5.0 to 6.5) Specific Gravity = 1.02 Single dose container. The overwrap is a moisture and oxygen barrier. Do not remove unit from overwrap until ready for use. Visually inspect overwrap for tears or holes. Discard unit if overwrap is damaged. Use unit promptly when overwrap is opened. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard solution as sterility may be impaired. COLOR VARIATION FROM PALE YELLOW TO YELLOW IS NORMAL AND DOES NOT ALTER EFFICACY. Rx only 7 OTHER icumedical F WR-0544 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA PRINCIPAL DISPLAY PANEL - 500 mL Overwrap Label"]},"tags":[{"label":"Amino Acid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Solution","category":"form"},{"label":"Active","category":"status"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE","source":"FDA FAERS","actionTaken":"50 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"42 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"39 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"36 reports"},{"date":"","signal":"CHILLS","source":"FDA FAERS","actionTaken":"35 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"35 reports"},{"date":"","signal":"NO ADVERSE EVENT","source":"FDA FAERS","actionTaken":"30 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"28 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"24 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"24 reports"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Pyrexia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hypertension","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Vomiting","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hemoglobin decreased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Protein total decreased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hypokalemia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Blood potassium decreased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Gamma-glutamyltransferase increased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hyperglycemia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Blood alkaline phosphatase increased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Blood calcium decreased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Prothrombin time prolonged","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Pruritus","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Tachycardia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Cholestasis","drugRate":"reported","severity":"unknown"},{"effect":"Infection","drugRate":"reported","severity":"unknown"},{"effect":"Subependymal hemorrhage","drugRate":"reported","severity":"serious"}],"contraindications":["Untreated anuria","Hepatic coma","Inborn errors of amino acid metabolism, including maple syrup urine disease and isovaleric acidemia","Hypersensitivity to one or more amino acids in the solution"],"specialPopulations":{"Pregnancy":"PERIKABIVEN (R) should be given to pregnant woman only if clearly needed. Severe malnutrition in pregnant woman is associated with preterm delivery, low birth weight, intrauterine growth restriction, congenital malformations and perinatal mortality. Parenteral nutrition should be considered if pregnant womans nutritional requirements cannot be fulfilled by oral or enteral intake.","Geriatric use":"Clinical Studies of Aminosyn II have not been performed to determine whether patients over 65 years of age respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.","Paediatric use":"Safety and effectiveness of solutions from flexible plastic containers in pediatric patients have not been well established. Clinical Studies of Aminosyn II have not been performed to determine whether patients over 65 years of age respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. If required, adjust the volume of PERIKABIVEN (R) administered based on serum electrolyte levels and fluid balance.","Renal impairment":"Patients on dialysis or continuous renal replacement therapy may require additional protein supplementation to meet nutritional requirements. If required, adjust the volume of PERIKABIVEN (R) administered based on serum electrolyte levels and fluid balance."}},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ALANINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:21:31.504698+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Alanine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:21:39.355504+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:22:10.655025+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:21:37.228751+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:21:30.567218+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALANINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:21:37.800424+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:21:24.397357+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:21:24.397392+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:22:05.374666+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:21:24.397398+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:21:39.759986+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL279597/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:21:38.918505+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS Local reactions consisting of erythema, phlebitis and thrombosis at the infusion site have occurred with peripheral intravenous infusion of amino acids particularly if other substances, such as antibiotics, are also administered through the same site. In such cases the infusion site should be changed promptly to another vein. Use of large peripheral veins, inline filters, and slowing the rate of infusion may reduce the incidence of local venous irritation. Electrolyte additives","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:21:43.258591+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:21:48.083438+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA019398","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:21:24.397401+00:00"}},"allNames":"l-alanine","offLabel":[],"synonyms":["alanine","L-Alanine","(S)-Alanine"],"timeline":[],"aiSummary":"L-Alanine is a marketed nutritional support product specifically indicated for infants and young children, currently holding a niche position in the pediatric nutrition market. Its key strength lies in its mechanism of action, which supports protein synthesis and energy production, essential for the growth and development of young patients. The primary risk to consider is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.","brandName":"L-Alanine","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"Amino Acid [EPC]","explanation":"","oneSentence":"","technicalDetail":"L-Alanine is a non-essential amino acid that serves as a precursor for pyruvate, a key intermediate in the citric acid cycle, and can also be converted to glutamate, which is involved in neurotransmitter synthesis and glutamine production."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Alanine","title":"Alanine","extract":"Alanine, or α-alanine, is an α-amino acid that is used in the biosynthesis of proteins. It contains an amine group and a carboxylic acid group, both attached to the central carbon atom which also carries a methyl group side chain. Consequently it is classified as a non-polar, aliphatic α-amino acid. Under biological conditions, it exists in its zwitterionic form with its amine group protonated and its carboxyl group deprotonated. It is non-essential to humans as it can be synthesized metabolically and does not need to be present in the diet. It is encoded by all codons starting with GC."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4255","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ALANINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALANINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Alanine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T08:31:25.877271","_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-19T23:22:10.655727+00:00","fieldsConflicting":16,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"alanine","indications":{"approved":[{"id":"alanine-nutritional-support-in-infants","name":"Nutritional Support in Infants and Young Children","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Infants (including low birth weight) and young children","pivotalTrial":null,"restrictions":[],"patientPopulation":"Infants (including low birth weight) and young children","diagnosticRequired":null,"brandNameForIndication":"L-Alanine"},{"id":"alanine-prevent-nitrogen-and-weight-lo","name":"Prevent Nitrogen and Weight Loss","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Infants and young children with conditions affecting protein intake or requirements","pivotalTrial":null,"restrictions":[],"patientPopulation":"Infants and young children with conditions affecting protein intake or requirements","diagnosticRequired":null,"brandNameForIndication":"L-Alanine"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":["Ganglioneuroblastoma, Nodular","Neuroblastoma"],"enrollment":478,"completionDate":"2029-12-31"},{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":["Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type"],"enrollment":94,"completionDate":"2026-12-23"},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":["Acute Myeloid Leukemia"],"enrollment":244,"completionDate":"2028-05-15"},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":["Acute Myeloid Leukemia","Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm","Acute Myeloid Leukemia Post Cytotoxic Therapy","Acute Myeloid Leukemia, Myelodysplasia-Related","Myelodysplastic Syndrome"],"enrollment":2000,"completionDate":"2029-05-15"},{"nctId":"NCT03493178","phase":"EARLY_PHASE1","title":"Glutathione in Mild Cognitive Impairment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2018-04-19","conditions":["Mild Cognitive Impairment"],"enrollment":60,"completionDate":"2026-12-31"},{"nctId":"NCT03494569","phase":"PHASE1","title":"Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2018-07-06","conditions":["Acute Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia in Remission","Acute Myeloid Leukemia","Acute Myeloid Leukemia in Remission","Hematopoietic Cell Transplantation Recipient","Minimal Residual Disease","Myelodysplastic Syndrome","Secondary Acute Myeloid Leukemia"],"enrollment":36,"completionDate":"2026-06-11"},{"nctId":"NCT07478497","phase":"NA","title":"30 Day Insulin Balance Metabolic Health Optimization Protocol","status":"RECRUITING","sponsor":"Efforia, Inc","startDate":"2025-10-21","conditions":["Insulin"],"enrollment":100,"completionDate":"2026-10-21"},{"nctId":"NCT06667726","phase":"PHASE2","title":"An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-10-01","conditions":["Malignant Brain Neoplasm"],"enrollment":47,"completionDate":"2029-10-08"},{"nctId":"NCT04384692","phase":"PHASE2","title":"Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-18","conditions":["Primary Myelofibrosis","Secondary Myelofibrosis"],"enrollment":53,"completionDate":"2030-04-23"},{"nctId":"NCT00602641","phase":"PHASE3","title":"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02-29","conditions":["Multiple Myeloma"],"enrollment":306,"completionDate":"2026-02-22"},{"nctId":"NCT07442552","phase":"","title":"Perioperative Sepsis. An Epigenetic Perspective","status":"RECRUITING","sponsor":"Carol Davila University of Medicine and Pharmacy","startDate":"2026-01-20","conditions":["Sepsis Abdominal"],"enrollment":40,"completionDate":"2026-04-10"},{"nctId":"NCT04077723","phase":"PHASE1,PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-08-13","conditions":["Lymphoma, Non-Hodgkin"],"enrollment":498,"completionDate":"2027-03-31"},{"nctId":"NCT06817889","phase":"PHASE2","title":"Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-12-23","conditions":["Hematopoietic and Lymphatic System Neoplasm","Autoimmune Disease","Respiratory Syncytial Virus Infection"],"enrollment":60,"completionDate":"2027-11-30"},{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":["Autoimmune Disease","Neurologic Autoimmune Disease","Autologous Transplant Autoimmune","Multiple Sclerosis Transplant","MS Stem Cell Transplant","Multiple Sclerosis Stem Cell Transplant","Stiff Person Syndrome","HCT for Neurologic Autoimmune Disorders","CIDP Transplant","Myasthenia Gravis Transplant","Autoimmune Nervous System Disorder","Central Nervous System Vasculitis","Cerebellar Degeneration","Chronic Inflammatory Demyelinating Polyneuropathy","Lambert Eaton Myasthenic Syndrome","Myasthenia Gravis","Neuromyelitis Optica","Opsoclonus Myoclonus Syndrome","Rasmussen Subacute Encephalitis"],"enrollment":53,"completionDate":"2030-01-31"},{"nctId":"NCT07228624","phase":"PHASE2","title":"Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-02-04","conditions":["Myelodysplastic/Myeloproliferative Neoplasm","Primary Myelofibrosis","Secondary Myelofibrosis"],"enrollment":50,"completionDate":"2030-09-01"},{"nctId":"NCT05504291","phase":"PHASE2","title":"A Study to Give Treatment Inside the Eye to Treat Retinoblastoma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2022-11-04","conditions":["Bilateral Retinoblastoma","Childhood Intraocular Retinoblastoma","Group D Retinoblastoma","Stage I Retinoblastoma","Unilateral Retinoblastoma"],"enrollment":26,"completionDate":"2028-03-31"},{"nctId":"NCT07397689","phase":"","title":"Early Sepsis Recognition Tool","status":"NOT_YET_RECRUITING","sponsor":"KK Women's and Children's Hospital","startDate":"2026-02","conditions":["Infection","Sepsis"],"enrollment":40000,"completionDate":"2028-12"},{"nctId":"NCT07404540","phase":"NA","title":"Effect of β-alanine Supplementation and Training on Ergogenic Measures and Plasma Metabolites in Untrained Young Adults","status":"COMPLETED","sponsor":"University of Pecs","startDate":"2012-01","conditions":["Dietary Supplementation","Healthy Vollunteer"],"enrollment":43,"completionDate":"2012-03"},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":["Chronic Kidney Diseases","MAFLD"],"enrollment":90,"completionDate":"2028-12-31"},{"nctId":"NCT03048240","phase":"NA","title":"INtraoperative photoDYnamic Therapy of GliOblastoma","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2017-05-05","conditions":["Glioblastoma"],"enrollment":10,"completionDate":"2021-04-28"},{"nctId":"NCT05781321","phase":"PHASE2","title":"Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-03-23","conditions":["Glioblastoma"],"enrollment":170,"completionDate":"2028-07-02"},{"nctId":"NCT07377786","phase":"","title":"Study of Prognostic Values of Platelet Indices and Inflammatory Markers in Patients With HELLP Syndrome.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-02-01","conditions":["HELLP Syndrome"],"enrollment":60,"completionDate":"2026-12"},{"nctId":"NCT07025226","phase":"EARLY_PHASE1","title":"Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-12","conditions":["Glioma"],"enrollment":10,"completionDate":"2027-09-01"},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":["Ganglioneuroblastoma","Localized Resectable Neuroblastoma","Localized Unresectable Neuroblastoma","Regional Neuroblastoma","Stage 4 Neuroblastoma","Stage 4S Neuroblastoma"],"enrollment":99,"completionDate":"2025-12-31"},{"nctId":"NCT06114498","phase":"","title":"Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2023-09-01","conditions":["Heart Failure With Preserved Ejection Fraction","Obesity, Mild","Decompensated Heart Failure"],"enrollment":240,"completionDate":"2026-07-31"},{"nctId":"NCT06958107","phase":"","title":"LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2025-08-21","conditions":["Sarcoma"],"enrollment":300,"completionDate":"2030-01"},{"nctId":"NCT07350512","phase":"NA","title":"Investigating the Acute Effects of Increasing Alanine Exposure in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"Nicolai Jacob Wewer Albrechtsen","startDate":"2026-01-20","conditions":["Glucose Metabolism","Glucagon"],"enrollment":15,"completionDate":"2027-01-20"},{"nctId":"NCT05569759","phase":"PHASE2","title":"A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)","status":"COMPLETED","sponsor":"Kezar Life Sciences, Inc.","startDate":"2023-05-23","conditions":["Autoimmune Hepatitis"],"enrollment":24,"completionDate":"2025-04-30"},{"nctId":"NCT04370301","phase":"PHASE2","title":"Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-02-09","conditions":["Primary Myelofibrosis","Secondary Myelofibrosis"],"enrollment":20,"completionDate":"2029-08-31"},{"nctId":"NCT07319052","phase":"NA","title":"β-Alanine for Kickboxing Anaerobic Performance","status":"COMPLETED","sponsor":"Salih ÇABUK","startDate":"2025-04-30","conditions":["Athletic Performance Enhancement (Kickboxing)","Anaerobic Performance","Strength Endurance","Neuromuscular Power","Nutritional Supplementation (β-Alanine)"],"enrollment":28,"completionDate":"2025-06-04"},{"nctId":"NCT04022239","phase":"PHASE1,PHASE2","title":"Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-03-13","conditions":["Hematopoietic and Lymphoid System Neoplasm"],"enrollment":25,"completionDate":"2027-07-31"},{"nctId":"NCT06881472","phase":"NA","title":"The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Asger Lund, MD","startDate":"2025-01-01","conditions":["Type 1 Diabetes"],"enrollment":10,"completionDate":"2026-01-16"},{"nctId":"NCT07155447","phase":"PHASE3","title":"Perioperative Nutrition Optimization for Reducing Complications After Surgical Fracture Fixation","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-06-01","conditions":["Lower Extremity Fracture"],"enrollment":1000,"completionDate":"2027-12-31"},{"nctId":"NCT07276204","phase":"PHASE2","title":"Betaine vs. Placebo for Serologically Diagnosed Metabolic Dysfunction-associated Steatohepatitis (MASH)","status":"NOT_YET_RECRUITING","sponsor":"Southern California Institute for Research and Education","startDate":"2026-03-31","conditions":["MASH - Metabolic Dysfunction-Associated Steatohepatitis"],"enrollment":70,"completionDate":"2035-12-31"},{"nctId":"NCT07317414","phase":"PHASE2","title":"β-alanine in the Treatment of Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-12-24","conditions":["Hepatocellular Carcinoma"],"enrollment":158,"completionDate":"2030-12-05"},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":["Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Mixed Phenotype Acute Leukemia","Myelodysplastic Syndrome"],"enrollment":435,"completionDate":"2026-06-30"},{"nctId":"NCT06083480","phase":"PHASE4","title":"Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2024-12-06","conditions":["Osteoarthritis, Knee","Total Knee Arthroplasty","Chronic Postsurgical Pain"],"enrollment":148,"completionDate":"2029-03"},{"nctId":"NCT03346135","phase":"PHASE2","title":"Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-07-17","conditions":["Plasma Cell Myeloma","Secondary Amyloidosis"],"enrollment":31,"completionDate":"2026-07-01"},{"nctId":"NCT02251821","phase":"PHASE2","title":"JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2014-10-20","conditions":["Primary Myelofibrosis","Secondary Myelofibrosis"],"enrollment":61,"completionDate":"2025-12-28"},{"nctId":"NCT04820036","phase":"NA","title":"A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-05-06","conditions":["Non-alcoholic Steatohepatitis (NASH)","Endoscopic Sleeve Gastroplasty","Non-alcoholic Fatty Liver Disease (NAFLD)","Endoscopic Ultrasound","Liver Function","Obesity","Liver Fibroses"],"enrollment":20,"completionDate":"2027-12-24"},{"nctId":"NCT00114101","phase":"PHASE3","title":"Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-12-15","conditions":["DS Stage I Multiple Myeloma","DS Stage II Multiple Myeloma","DS Stage III Multiple Myeloma","Refractory Multiple Myeloma","Smoldering Multiple Myeloma"],"enrollment":460,"completionDate":"2026-02-22"},{"nctId":"NCT06944275","phase":"","title":"Characterising the Loss of Haemostasis in Haemorrhagic Fever With Renal Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2026-05-01","conditions":["Haemorrhagic Fever With Renal Syndrome"],"enrollment":62,"completionDate":"2027-08-31"},{"nctId":"NCT05797714","phase":"NA","title":"The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2022-06-08","conditions":["HBV Infection","Chronic Hepatitis b"],"enrollment":200,"completionDate":"2028-04-30"},{"nctId":"NCT07115563","phase":"NA","title":"Daily Amino Acid Supplementation for People With Parkinson's Disease","status":"RECRUITING","sponsor":"Cristina Colon-Semenza","startDate":"2025-10-31","conditions":["Parkinson Disease (PD)"],"enrollment":30,"completionDate":"2027-11"},{"nctId":"NCT06195891","phase":"PHASE1","title":"Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-05-24","conditions":["Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Myelodysplastic Syndrome"],"enrollment":33,"completionDate":"2027-06-21"},{"nctId":"NCT03259503","phase":"PHASE1","title":"Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-09-13","conditions":["Recurrent Diffuse Large B-Cell Lymphoma","Recurrent T-Cell Non-Hodgkin Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Hodgkin Lymphoma","Refractory T-Cell Non-Hodgkin Lymphoma"],"enrollment":50,"completionDate":"2025-11-05"},{"nctId":"NCT02727803","phase":"PHASE2","title":"Personalized NK Cell Therapy in CBT","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-19","conditions":["Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Acute Biphenotypic Leukemia","Acute Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia in Remission","Acute Myeloid Leukemia With Myelodysplasia-Related Changes","Acute Myeloid Leukemia With Variant MLL Translocations","B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Chemotherapy-Related Leukemia","Chronic Myelomonocytic Leukemia","Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","ISS Stage II Plasma Cell Myeloma","ISS Stage III Plasma Cell Myeloma","Myelodysplastic Syndrome","Myelodysplastic Syndrome With Excess Blasts","Myelodysplastic Syndrome With Gene Mutation","Myelodysplastic/Myeloproliferative Neoplasm","Previously Treated Myelodysplastic Syndrome","Recurrent Acute Myeloid Leukemia","Recurrent Adult Acute Myeloid Leukemia","Recurrent Hodgkin Lymphoma","Recurrent Non-Hodgkin Lymphoma","Refractory Acute Lymphoblastic Leukemia","Refractory Adult Acute Lymphoblastic Leukemia","Secondary Acute Myeloid Leukemia","Therapy-Related Myelodysplastic Syndrome"],"enrollment":100,"completionDate":"2027-05-31"},{"nctId":"NCT05031897","phase":"PHASE2","title":"Two Step Haplo With Radiation Conditioning","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-10-25","conditions":["Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Adult T-Cell Leukemia/Lymphoma","Aplastic Anemia","Chronic Lymphocytic Leukemia","Chronic Myeloid Leukemia, BCR-ABL1 Positive","Chronic Myelomonocytic Leukemia","Essential Thrombocythemia","Hematopoietic and Lymphatic System Neoplasm","Hodgkin Lymphoma","Multiple Myeloma","Myelodysplastic Syndrome","Myelofibrosis","Myeloid Neoplasm","Non-Hodgkin Lymphoma","Polycythemia Vera","Small Lymphocytic Lymphoma"],"enrollment":63,"completionDate":"2032-04"},{"nctId":"NCT03856216","phase":"PHASE2","title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-28","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia","Lymphocytic Neoplasm","Lymphoma"],"enrollment":15,"completionDate":"2025-10-13"},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":["Ganglioneuroblastoma","High Risk Neuroblastoma"],"enrollment":42,"completionDate":"2026-09-19"},{"nctId":"NCT04731259","phase":"PHASE1,PHASE2","title":"Study to Evaluate the Safety of ATR-04","status":"WITHDRAWN","sponsor":"Azitra Inc.","startDate":"2024-01","conditions":["Epidermal Growth Factor","Papulopustular Rosacea"],"enrollment":0,"completionDate":"2026-01"},{"nctId":"NCT05400733","phase":"NA","title":"Prandial Metabolic Phenotype in Adults","status":"RECRUITING","sponsor":"Texas A&M University","startDate":"2022-06-24","conditions":["Protein Metabolism"],"enrollment":50,"completionDate":"2026-09"},{"nctId":"NCT06022939","phase":"PHASE3","title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-07-01","conditions":["AL Amyloidosis"],"enrollment":338,"completionDate":"2030-10-29"},{"nctId":"NCT07167251","phase":"","title":"Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-08-25","conditions":["Immune Related Adverse Events","Immune-Mediated Hepatitis","Cancer"],"enrollment":63,"completionDate":"2026-12-31"},{"nctId":"NCT06003400","phase":"NA","title":"Proof of Concept Open Label, Clinical Trial to Evaluate the Safety and Efficacy of the \"FITT\" Device in Diabetic Foot Ulcers Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tri.O Medical LTD","startDate":"2023-03-29","conditions":["Diabetic Foot Ulcer"],"enrollment":20,"completionDate":"2026-01"},{"nctId":"NCT06737380","phase":"PHASE1","title":"UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients","status":"RECRUITING","sponsor":"LiveKidney.Bio","startDate":"2025-01-07","conditions":["SLE","Lupus","Systemic Lupus Erthematosus","Systemic Lupus Erythematosus","Systemic Lupus Erythematosus (SLE)"],"enrollment":10,"completionDate":"2026-07"},{"nctId":"NCT07144501","phase":"NA","title":"Prevalence of Liver Dysfunction in Pediatric Patients With Congenital Heart Disease at Assiut.","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-09-15","conditions":["Congenital Heart Disease","Liver Dysfunction"],"enrollment":40,"completionDate":"2026-03-15"},{"nctId":"NCT06387667","phase":"NA","title":"Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections","status":"NOT_YET_RECRUITING","sponsor":"New Valley University","startDate":"2025-12-01","conditions":["Immunocompromised ICU Patients With Respiratory Tract Infections"],"enrollment":250,"completionDate":"2027-06-01"},{"nctId":"NCT05230862","phase":"NA","title":"Does a Multi-ingredient Pre-workout Supplement Enhance Cycling Time Trial Performance?","status":"COMPLETED","sponsor":"University of Exeter","startDate":"2021-12-02","conditions":["Healthy Volunteers"],"enrollment":12,"completionDate":"2022-09-30"},{"nctId":"NCT07092930","phase":"PHASE3","title":"Effects of β-alanine and Sodium Bicarbonate Supplementation on Physical Capacity and Biochemical Markers Concentrations","status":"RECRUITING","sponsor":"Poznan University of Physical Education","startDate":"2023-10-01","conditions":["Supplementation","Sports","Female Athletes"],"enrollment":100,"completionDate":"2025-12"},{"nctId":"NCT06620835","phase":"PHASE2","title":"Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib","status":"RECRUITING","sponsor":"Groupe Francais De Pneumo-Cancerologie","startDate":"2025-06-19","conditions":["NSCLC"],"enrollment":45,"completionDate":"2030-10-01"},{"nctId":"NCT06287944","phase":"PHASE1","title":"225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-07-01","conditions":["Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Myelodysplastic Syndrome"],"enrollment":15,"completionDate":"2028-05-19"},{"nctId":"NCT07081464","phase":"","title":"Locus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome)","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-10-15","conditions":["Ondine Syndrome (Congenital Central Hypoventilation Syndrome)"],"enrollment":25,"completionDate":"2027-10-15"},{"nctId":"NCT06954662","phase":"EARLY_PHASE1","title":"A Targeted Amino Acid Supplement for People With Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"UConn Health","startDate":"2025-05-22","conditions":["Parkinson Disease, Idiopathic"],"enrollment":15,"completionDate":"2025-09"},{"nctId":"NCT06377111","phase":"PHASE1","title":"A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-06-24","conditions":["Melanoma (Skin)"],"enrollment":12,"completionDate":"2026-08"},{"nctId":"NCT05560009","phase":"","title":"An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-11-10","conditions":["Recurrent Soft Tissue Sarcoma","Resectable Soft Tissue Sarcoma","Soft Tissue Sarcoma"],"enrollment":9,"completionDate":"2024-07-09"},{"nctId":"NCT05139004","phase":"PHASE1","title":"90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-07-19","conditions":["Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Myelodysplastic Syndrome","Secondary Acute Myeloid Leukemia"],"enrollment":7,"completionDate":"2027-06-13"},{"nctId":"NCT03778294","phase":"PHASE2","title":"18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-03-28","conditions":["Glioblastoma","Malignant Glioma"],"enrollment":43,"completionDate":"2023-11-26"},{"nctId":"NCT04530487","phase":"PHASE2","title":"Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-19","conditions":["Desmoplastic Small Round Cell Tumor","Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","Recurrent Desmoplastic Small Round Cell Tumor","Recurrent Malignant Peripheral Nerve Sheath Tumor","Recurrent Malignant Solid Neoplasm","Recurrent Neuroblastoma","Recurrent Rhabdomyosarcoma","Refractory Desmoplastic Small Round Cell Tumor","Refractory Malignant Peripheral Nerve Sheath Tumor","Refractory Malignant Solid Neoplasm","Refractory Neuroblastoma","Refractory Rhabdomyosarcoma"],"enrollment":1,"completionDate":"2024-08-26"},{"nctId":"NCT06815003","phase":"PHASE2","title":"Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-04-18","conditions":["Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Graft Versus Host Disease","Myelodysplastic Syndrome","Myeloproliferative Neoplasm"],"enrollment":35,"completionDate":"2028-10-15"},{"nctId":"NCT03118492","phase":"PHASE1","title":"Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-05-24","conditions":["Secondary Myelofibrosis"],"enrollment":22,"completionDate":"2026-05-26"},{"nctId":"NCT07023159","phase":"","title":"Predicting 28-Day Survival in OHCA Patients","status":"COMPLETED","sponsor":"Haseki Training and Research Hospital","startDate":"2023-05-01","conditions":["Out of Hospital Cardiac Arrest","Cardiac Arrest (CA)"],"enrollment":327,"completionDate":"2024-06-01"},{"nctId":"NCT06809270","phase":"NA","title":"Moderate Intensity Intermittent Walking in Postmenopausal Women","status":"COMPLETED","sponsor":"Wissal Abassi","startDate":"2024-09-23","conditions":["Liver Enzymes","Inflammatory Markers"],"enrollment":36,"completionDate":"2024-12-22"},{"nctId":"NCT04740580","phase":"EARLY_PHASE1","title":"Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2022-02-15","conditions":["Alzheimer Disease"],"enrollment":52,"completionDate":"2026-12-31"},{"nctId":"NCT06996119","phase":"PHASE1","title":"Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-05-25","conditions":["Acute Myeloid Leukemia","Graft Versus Host Disease","Myelodysplastic Syndrome"],"enrollment":15,"completionDate":"2027-05-25"},{"nctId":"NCT06579391","phase":"NA","title":"Targeted Nutritional Supplement After Lumbar Spine Surgery: A Randomized, Placebo-Controlled, Double-Blind Trial","status":"WITHDRAWN","sponsor":"University of California, Irvine","startDate":"2025-01","conditions":["Lumbar Spinal Stenosis"],"enrollment":0,"completionDate":"2026-07"},{"nctId":"NCT06995209","phase":"NA","title":"Study on How Pre-Workout Supplements Affect Shooting Accuracy in Trained Basketball Players","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Hellenic University","startDate":"2024-10-01","conditions":["Athletic Performance"],"enrollment":12,"completionDate":"2025-06-30"},{"nctId":"NCT03548064","phase":"PHASE1","title":"A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-10","conditions":["Gastroenteritis Escherichia Coli","Immunisation"],"enrollment":75,"completionDate":"2020-12-31"},{"nctId":"NCT03583424","phase":"PHASE1,PHASE2","title":"Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2018-09-10","conditions":["Hematopoietic Cell Transplantation Recipient","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Non-Hodgkin Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Follicular Lymphoma","Refractory Marginal Zone Lymphoma","Refractory Non-Hodgkin Lymphoma","Refractory Transformed Indolent Non-Hodgkin Lymphoma"],"enrollment":19,"completionDate":"2021-09-30"},{"nctId":"NCT01729091","phase":"PHASE2","title":"Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-06-10","conditions":["Plasma Cell Leukemia","Plasma Cell Myeloma"],"enrollment":72,"completionDate":"2024-06-25"},{"nctId":"NCT01808352","phase":"","title":"HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2013-08-15","conditions":["HIV"],"enrollment":226,"completionDate":"2015-09-30"},{"nctId":"NCT06953557","phase":"","title":"Evaluation of the Salivary-free Amino Acids Levels (Glycine , Proline , Lysine , and Alanine ) With Caries Activity","status":"NOT_YET_RECRUITING","sponsor":"Al-Mustansiriyah University","startDate":"2025-04-30","conditions":["Dental Caries"],"enrollment":80,"completionDate":"2025-06-30"},{"nctId":"NCT02797470","phase":"PHASE1,PHASE2","title":"Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"AIDS Malignancy Consortium","startDate":"2016-06-23","conditions":["HIV Infection","Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Plasmablastic Lymphoma","Recurrent Adult Hodgkin Lymphoma","Recurrent Adult Non-Hodgkin Lymphoma","Recurrent Burkitt Lymphoma","Recurrent Follicular Lymphoma","Stage III Follicular Lymphoma","Stage III Mantle Cell Lymphoma","Stage IV Follicular Lymphoma","Stage IV Mantle Cell Lymphoma"],"enrollment":11,"completionDate":"2036-03"},{"nctId":"NCT04339101","phase":"PHASE2","title":"Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-11-11","conditions":["Acute Leukemia","Hematologic and Lymphocytic Disorder","Myelodysplastic Syndrome","Primary Myelofibrosis","Secondary Myelofibrosis"],"enrollment":59,"completionDate":"2026-01-20"},{"nctId":"NCT02506959","phase":"PHASE2","title":"Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":["Plasma Cell Leukemia","Plasmacytoma","Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma"],"enrollment":83,"completionDate":"2024-06-03"},{"nctId":"NCT02947750","phase":"PHASE2","title":"Neurovascular Transduction During Exercise in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Emory University","startDate":"2016-10","conditions":["Renal Insufficiency, Chronic"],"enrollment":150,"completionDate":"2026-01"},{"nctId":"NCT06283082","phase":"NA","title":"Oxalate Excretion Profile in Patients with a Heterozygous Mutation of the AGXT (alanine-glyoxylate Aminotransferase) Gene","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-12-11","conditions":["Hyperoxaluria (Disorder)"],"enrollment":25,"completionDate":"2026-03"},{"nctId":"NCT04233255","phase":"","title":"Role of Ultrasound in Diagnosis of Muscle Diseases","status":"COMPLETED","sponsor":"Assiut University","startDate":"2020-04-01","conditions":["Ultrasound","Muscle Disease"],"enrollment":128,"completionDate":"2024-07-01"},{"nctId":"NCT04119843","phase":"PHASE3","title":"Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function","status":"COMPLETED","sponsor":"Ascelia Pharma AB","startDate":"2020-02-19","conditions":["Known or Suspected Focal Liver Lesions","Severe Renal Impairment"],"enrollment":87,"completionDate":"2023-02-17"},{"nctId":"NCT05435638","phase":"PHASE1","title":"Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases","status":"COMPLETED","sponsor":"Kamari Pharma Ltd","startDate":"2022-07-17","conditions":["Punctate Palmoplantar Keratoderma Type 1","Pachyonychia Congenita"],"enrollment":14,"completionDate":"2024-09-05"},{"nctId":"NCT04656028","phase":"NA","title":"Genetic Testing and Motivational Counseling for FH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2020-06-15","conditions":["Hypercholesterolemia, Familial","Hypercholesterolemia, Familial, 1","Hypercholesterolemia, Familial, 2","Hypercholesterolemia, Familial, 3","Hypercholesterolemia, Familial, 4","Hypercholesterolemia, Familial, 4, Autosomal Recessive","Familial Hypercholesterolemia With Hyperlipemia","Hypercholesterolemia, Autosomal Dominant, Type B","Hypercholesterolemia, Autosomal Dominant","Hypercholesterolemia, Autosomal Dominant, 3","Apolipoprotein B-100, Familial Defective","Genetic Testing","Motivational Interviewing","Therapeutic Adherence","Therapeutic Adherence and Compliance","Treatment Adherence","Medication Adherence","Treatment Adherence and Compliance","Patient Adherence","Compliance","Patient Compliance","Familial Hypercholesterolemia","Familial Hypercholesterolemia - Heterozygous","Adherence, Patient","Adherence, Medication","Adherence"],"enrollment":180,"completionDate":"2025-03-30"},{"nctId":"NCT06645691","phase":"PHASE2","title":"Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body","status":"RECRUITING","sponsor":"National Heart Centre Singapore","startDate":"2024-10-17","conditions":["Heart Failure","Cardiometabolic Syndrome","Cancer Diagnosis","Cardiovascular Diseases","Healthy Volunteers"],"enrollment":200,"completionDate":"2028-05-31"},{"nctId":"NCT04932512","phase":"PHASE2","title":"A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2021-06-17","conditions":["Steatohepatitis, Nonalcoholic"],"enrollment":160,"completionDate":"2024-02-28"},{"nctId":"NCT04521946","phase":"PHASE1","title":"Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-14","conditions":["Anaplastic Ependymoma","Atypical Teratoid/Rhabdoid Tumor","Central Nervous System Germ Cell Tumor","Choroid Plexus Carcinoma","Intracranial Myeloid Sarcoma","Malignant Brain Neoplasm","Malignant Glioma","Medulloblastoma","Primitive Neuroectodermal Tumor","Recurrent Anaplastic Ependymoma","Recurrent Atypical Teratoid/Rhabdoid Tumor","Recurrent Malignant Brain Neoplasm","Recurrent Malignant Glioma","Recurrent Medulloblastoma","Recurrent Primitive Neuroectodermal Tumor"],"enrollment":0,"completionDate":"2022-12-20"},{"nctId":"NCT04513288","phase":"NA","title":"ICITRU : Randomized Trial of Immunonutrition With L-citrulline in Patients Hospitalized in Intensive Care for Sepsis or Septic Shock","status":"RECRUITING","sponsor":"Rennes University Hospital","startDate":"2022-05-20","conditions":["Sepsis","Septic Shock"],"enrollment":130,"completionDate":"2026-11-20"},{"nctId":"NCT05218356","phase":"PHASE2","title":"Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19","status":"RECRUITING","sponsor":"Code Pharma","startDate":"2022-01-20","conditions":["COVID-19"],"enrollment":130,"completionDate":"2025-07-20"},{"nctId":"NCT03418779","phase":"PHASE2,PHASE3","title":"Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2019-07-04","conditions":["IgA Nephropathy at High Risk of Developing ESRD"],"enrollment":60,"completionDate":"2024-12-31"},{"nctId":"NCT06607562","phase":"NA","title":"Effectiveness and Safety of Probiotics in Protecting Liver Function","status":"RECRUITING","sponsor":"Wecare Probiotics Co., Ltd.","startDate":"2024-06-03","conditions":["Alcohol Abuse"],"enrollment":80,"completionDate":"2025-04-15"},{"nctId":"NCT03691376","phase":"PHASE1","title":"Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-03-08","conditions":["Platinum-Resistant Fallopian Tube Carcinoma","Platinum-Resistant Ovarian Carcinoma","Platinum-Resistant Primary Peritoneal Carcinoma","Platinum-Sensitive Fallopian Tube Carcinoma","Platinum-Sensitive Ovarian Carcinoma","Platinum-Sensitive Primary Peritoneal Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Refractory Fallopian Tube Carcinoma","Refractory Ovarian Carcinoma","Refractory Primary Peritoneal Carcinoma"],"enrollment":4,"completionDate":"2024-06-24"},{"nctId":"NCT04546360","phase":"","title":"Spleen Stiffness Combined With Liver Stiffness Measured by 2D-SWE for the Screening of High-risk Varices in Compensated Advanced Chronic Liver Disease (CHESS2004)","status":"COMPLETED","sponsor":"Hepatopancreatobiliary Surgery Institute of Gansu Province","startDate":"2020-09-08","conditions":["Compensated Advanced Chronic Liver Disease","Variceal Hemorrhage"],"enrollment":381,"completionDate":"2022-12-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection, Solution","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"CLINIMIX"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"CLINIMIX E"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"ProcalAmine"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Travasol"},{"form":"INJECTION, EMULSION","route":"INTRAVENOUS","productName":"CLINIMIX"},{"form":"INJECTION, EMULSION","route":"INTRAVENOUS","productName":"Kabiven"},{"form":"INJECTION, EMULSION","route":"INTRAVENOUS","productName":"Perikabiven"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Clinisol"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Premasol - sulfite-free (Amino Acid)"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Aminosyn II"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Aminosyn-PF"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"FreAmine III"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"HepatAmine"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"ProSol"},{"form":"SOLUTION","route":"INTRAVENOUS","productName":"Plenamine"}]},"crossReferences":{"NUI":"N0000146978","MMSL":"NOCODE","NDDF":"004649","UNII":"OF5P57N2ZX","VUID":"4018667","CHEBI":"CHEBI:16449","VANDF":"4018667","INN_ID":"6161","RXNORM":"426","UMLSCUI":"C0001898","chemblId":"CHEMBL279597","ChEMBL_ID":"CHEMBL12198","KEGG_DRUG":"D00012","DRUGBANK_ID":"DB00160","PDB_CHEM_ID":" ALA","PUBCHEM_CID":"5950","SNOMEDCT_US":"58753009","IUPHAR_LIGAND_ID":"720","MESH_DESCRIPTOR_UI":"D000409"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":110762,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-08-17T00:00:00.000Z","mah":"OTSUKA ICU MEDCL","brand_name_local":null,"application_number":"NDA019398"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1994-07-11T00:00:00.000Z","mah":"OTSUKA ICU MEDCL","brand_name_local":null,"application_number":"NDA020015"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1999-04-15T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":"NDA020678"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2001-02-28T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":"ANDA020512"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2002-07-25T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":"NDA020734"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-19T23:22:10.655727+00:00","fieldsConflicting":16,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}